SCHEMBL26200096

SCHEMBL26200096

CC(C)(C)n1cnc2c(=O)[nH]c(NC(=O)COc3ccccc3)nc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
ALDH1A1 P00352 2/20 0.51
TP53 P04637 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
ALOX12 P18054 1/20 0.51
ALPL P05186 1/20 0.46
MAPT P10636 2/20 0.45
TSHR P16473 3/20 0.43
LMNA P02545 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
GAA P10253 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
ADORA2A P29274 1/20 0.41
KDM4E B2RXH2 1/20 0.41
THRB P10828 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21654897 0.81 RAF1 (0.43) NPC1RAB9ATP53SMN1; SMN2TSHR
SCHEMBL26200092 0.80 MEN1 (0.42) NPC1RAB9AALDH1A1SMN1; SMN2TSHR
SCHEMBL19841296 0.79 NPC1 (0.46) NPC1RAB9AALDH1A1TP53SMN1; SMN2
SCHEMBL25964378 0.79 MEN1 (0.55) ALDH1A1SMN1; SMN2TSHRLMNAGAA
SCHEMBL18349588 0.76 KDM4E (0.46) ALDH1A1SMN1; SMN2TSHRGAAMEN1
SCHEMBL2385400 0.76 TK1 (0.40) ALPLTSHRGAAMEN1KMT2A
SCHEMBL1970068 0.75 NPC1 (0.58) NPC1RAB9AALDH1A1TP53SMN1; SMN2
SCHEMBL30400675 0.74 TAS1R3 (0.60) ADORA3ADORA2AHPGD
SCHEMBL19399467 0.74 TAS1R3 (0.49) NPC1RAB9AALDH1A1TP53SMN1; SMN2
SCHEMBL16940301 0.74 TAS1R3 (0.49) NPC1RAB9AALDH1A1TP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271998-A1 SOLID SUPPORT FOR SYNTHESIZING NUCLEIC ACID SEQUENCES AND METHODS FOR MAKING AND USING UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271998-A1 SOLID SUPPORT FOR SYNTHESIZING NUCLEIC ACID SEQUENCES AND METHODS FOR MAKING AND USING RNGTT, NSUN2, POLN NPC1 1881/4885RAB9A 3828/4885ALDH1A1 4842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.